For Valentine's Day, Capture The Heart Of The Rosette Nebula

The Rosette Nebula is located in the Milky Way Galaxy roughly 5,000 light-years from us and is...

Mycroft Mark II - Artificial Intelligence Goes Open Source In A Voice Enabled Assistant

If you have used voice-enabled speaker devices like the Amazon Echo, which for some reason goes...

Organic Peat Moss Is Unsustainable And Harmful - Biochar Could Save The Day

Plant lovers love peat moss, it is the major component of potting mix and popular in greenhouses...

FDA Study Concludes The Supplement Kratom Is An Opioid

Though unusually ethically suspect supplement merchants have been marketing kratom, an analgesic...

User picture.
News StaffRSS Feed of this column.

News Releases From All Over The World, Right To You... Read More »

Currently, 1.5 billion people worldwide report chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out, with approximately 3-4.5% of the global population affected, and incidence rate increasing in line with increased age of the population. 

According to a recent estimate, the global pain management market is to reach US$60 Billion by 2015.[1]

Convergence Pharmaceuticals Limited has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

In a recent study, an area of the brain that initiates behavioral changes had greater activation in smokers who watched anti-smoking ads with strong arguments than ads with clever tricks like loud sounds and unexpected twists - and those smokers had significantly less nicotine metabolites in their urine when tested a month after viewing those ads.

Rainfall over the Hawaiian Islands has been declining since 1978.

Is the drying trend due to global warming? Yes, says a team of researchers who found that climate models don't have enough resolution to capture the diverse rainfall pattern over Hawaii, where dry and wet areas often lie only a mile or even less apart, and so devised a method called 'statistical downscaling.'

 They first got a take on the effects of the general drying trend on local heavy-rain days by reanalyzing observations from 1978 to 2010 at 12 rain-gauge stations spread throughout the islands. Studying hundreds of weather patterns during such days, they identified the typical atmospheric circulation patterns in the North Pacific that favor heavy rains over Hawaii. 

Bacterial vaginosis is a condition that occurs when the typical mix of microbes in the vagina is knocked off-kilter, sometimes resulting in a change in the consistency of vaginal fluids and an unpleasant odor. Bacterial vaginosis is diagnosed through examination of the vagina and tests of the vaginal fluids and then typically treated with antibiotics. 

The condition affects as many as one in every three women, making it more common than yeast infections. But bacterial vaginosis often does not cause significant symptoms, leaving many women unaware they have it, but it has been linked to preterm birth and increased risk of sexually transmitted diseases. New research points to a common species of bacteria as an important contributor to bacterial vaginosis.

On March 24th, 1993, astronomers David Levy and Carolyn and Eugene M. Shoemaker discovered the first comet observed orbiting a planet rather than the Sun.  Named Shoemaker-Levy 9 (SL9), it was found to be composed of 21 fragments. Soon after that, orbital studies showed that the comet had passed within Jupiter's Roche limit in July 1992. Inside this limit, the planet's tidal forces are strong enough to disintegrate a body held together by its own gravity, thus explaining SL9's fragmentation.  

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types.

Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders).